Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
The condition, which usually emerges several weeks after infection, is still rare, but can be dangerous. A higher percentage of them are really critically ill, one doctor said.
